BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morena M, Le May C, Chenine L, Arnaud L, Dupuy AM, Pichelin M, Leray-Moragues H, Chalabi L, Canaud B, Cristol JP, Cariou B. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol 2017;11:87-93. [PMID: 28391915 DOI: 10.1016/j.jacl.2016.10.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Doiron S, Paquette M, Baass A, Bollée G, Cardinal H, Bernard S. Association between circulating PCSK9 and proteinuria in nephrotic syndrome: A cross-sectional study. Clinical Biochemistry 2022. [DOI: 10.1016/j.clinbiochem.2022.08.002] [Reference Citation Analysis]
2 Lupo MG, Bressan A, Donato M, Canzano P, Camera M, Poggio P, Greco MF, Garofalo M, De Martin S, Panighel G, Ruscica M, Baragetti A, Bollati V, Faggin E, Rattazzi M, Catapano AL, Ferri N. PCSK9 promotes arterial medial calcification. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.01.015] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Vlad CE, Foia L, Pavel-Tanasa M, Toma V, Florea L, Voroneanu L, Apetrii M, Dodi G, Covic A. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania. Int Urol Nephrol 2021. [PMID: 34224064 DOI: 10.1007/s11255-021-02919-2] [Reference Citation Analysis]
4 Barbagallo CM, Cefalù AB, Giammanco A, Noto D, Caldarella R, Ciaccio M, Averna MR, Nardi E. Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation. Life (Basel) 2021;11:315. [PMID: 33916487 DOI: 10.3390/life11040315] [Reference Citation Analysis]
5 Didas N, Thitisopee W, Porntadavity S, Jeenduang N. Arylesterase activity but not PCSK9 levels is associated with chronic kidney disease in type 2 diabetes. Int Urol Nephrol 2020;52:1725-32. [PMID: 32661629 DOI: 10.1007/s11255-020-02547-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Aceña Á, Franco Peláez JA, Pello Lázaro AM, Gonzalez Parra E, Gonzalez Lorenzo Ó, Martínez-Milla J, Hernandez I, Martín-Mariscal ML, Lopez Castillo M, Kallmeyer A, Lorenzo O, González-Casaus ML, Egido J, Tuñón J. PCSK9 and HS-CRP Predict Progression of Aortic Stenosis in Patients with Stable Coronary Artery Disease. J Cardiovasc Transl Res 2021;14:238-45. [PMID: 32577988 DOI: 10.1007/s12265-020-10050-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Mathew RO, Rosenson RS, Lyubarova R, Chaudhry R, Costa SP, Bangalore S, Sidhu MS. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovasc Drugs Ther 2021;35:479-89. [PMID: 32556851 DOI: 10.1007/s10557-020-07020-x] [Reference Citation Analysis]
8 Cesaro A, Bianconi V, Gragnano F, Moscarella E, Fimiani F, Monda E, Scudiero O, Limongelli G, Pirro M, Calabrò P. Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. Biofactors 2020;46:367-80. [PMID: 31999032 DOI: 10.1002/biof.1619] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
9 Hwang HS, Kim JS, Kim YG, Lee SY, Ahn SY, Lee HJ, Lee DY, Lee SH, Moon JY, Jeong KH. Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients. J Clin Med 2020;9:E244. [PMID: 31963408 DOI: 10.3390/jcm9010244] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Stoekenbroek RM, Lambert G, Cariou B, Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol 2018;15:52-62. [PMID: 30367179 DOI: 10.1038/s41574-018-0110-5] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 17.7] [Reference Citation Analysis]
11 Pryor JB, Weber BR, Weber JV, Lockridge JB, Olyaei AJ. Lipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a review. Drugs Ther Perspect 2019;35:431-41. [DOI: 10.1007/s40267-019-00646-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
12 Bermudez-Lopez M, Forne C, Amigo N, Bozic M, Arroyo D, Bretones T, Alonso N, Cambray S, Del Pino MD, Mauricio D, Gorriz JL, Fernandez E, Valdivielso JM. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. Expert Opin Ther Targets 2019;23:619-30. [PMID: 31100024 DOI: 10.1080/14728222.2019.1620206] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
13 Strålberg T, Nordenskjöld A, Cao Y, Kublickiene K, Nilsson E. Proprotein convertase subtilisin/kexin type 9 and mortality in patients starting hemodialysis. Eur J Clin Invest 2019;49:e13113. [PMID: 30921469 DOI: 10.1111/eci.13113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Dincer N, Dagel T, Afsar B, Covic A, Ortiz A, Kanbay M. The effect of chronic kidney disease on lipid metabolism. Int Urol Nephrol 2019;51:265-77. [DOI: 10.1007/s11255-018-2047-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
15 Rasmussen LD, Bøttcher M, Ivarsen P, Jørgensen HS, Nyegaard M, Buttenschøn H, Gustafsen C, Glerup S, Bøtker HE, Svensson M, Winther S. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease. Nephrology Dialysis Transplantation 2020;35:632-9. [DOI: 10.1093/ndt/gfy257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
16 Zhang HW, Zhao X, Xu RX, Guo YL, Zhu CG, Wu NQ, Cui CJ, Dong Q, Li JJ. Relationship between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and Estimated Glomerular Filtration Rate in the General Chinese Population. Cardiorenal Med 2018;8:311-20. [PMID: 30121647 DOI: 10.1159/000490766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Dijk W, Le May C, Cariou B. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism? Trends Endocrinol Metab 2018;29:420-34. [PMID: 29665987 DOI: 10.1016/j.tem.2018.03.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
18 Zheng-lin B, Ortiz A. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting. Drugs 2018;78:215-29. [DOI: 10.1007/s40265-017-0858-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
19 Lu J, cheng B, Fang B, Meng Z, Zheng Y, Tian X, Guan S. Protective effects of allicin on 1,3-DCP-induced lipid metabolism disorder in HepG2 cells. Biomedicine & Pharmacotherapy 2017;96:1411-7. [DOI: 10.1016/j.biopha.2017.10.125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]